Abemaciclib, an oral CDK4/6 inhibitor developed by Eli Lilly, received FDA approval in September 2017 and holds distinction as the only CDK4/6 inhibitor approved for both early-stage and advanced HR+/HER2- breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.